uric acid has been researched along with dapagliflozin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 8 (53.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gilbert, RE | 1 |
| Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J | 1 |
| Alessi, F; Iqbal, N; Mansfield, TA; Parikh, S; Ptaszynska, A; Weber, MA | 1 |
| Dalama, B; Mesa, J | 1 |
| Chen, L; Tian, D; Wang, L; Xia, P; Xu, L; Zhao, Y; Zheng, H | 1 |
| Boulton, DW; Griffen, SC; Leslie, BR; Shen, W; Wilcox, CS | 1 |
| Atkin, SL; Butler, AE; Katsiki, N; Sahebkar, A; Yaribeygi, H | 1 |
| Cain, V; Correa-Rotter, R; Heerspink, HJL; Sartipy, P; Scholtes, RA; Sjöström, CD; Stefánsson, BV; Toto, RD; van Raalte, DH | 1 |
| Dronamraju, N; Erlandsson, F; Goldwater, R; Han, D; Johansson, S; Johnsson, E; Oscarsson, J; Parkinson, J; Stack, AG | 1 |
| de Boer, RA; Docherty, KF; Hammarstedt, A; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McDowell, K; McMurray, JJV; Morrow, DA; O'Meara, E; Ponikowski, P; Sabatine, MS; Sattar, N; Sjöstrand, M; Solomon, SD; Welsh, P | 1 |
| Dai, X; Hao, H; Li, Y; Ou, T; Wang, D; Wang, R; Wang, W; Yong, H | 1 |
| Doehner, W; Packer, M | 1 |
| Fukami, K; Kaida, Y; Shibata, R; Taguchi, K | 1 |
| Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Ponikowski, P; Sabatine, MS; Shah, SJ; Solomon, SD; Vaduganathan, M | 1 |
| Iwata, Y; Kawamura, Y; Mitani, W; Morimoto, M; Notsu, S; Tamai, S; Yamato, M | 1 |
5 review(s) available for uric acid and dapagliflozin
| Article | Year |
|---|---|
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
Topics: Animals; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney Glomerulus; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid | 2014 |
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Proteinuria; Risk; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uric Acid; Vascular Stiffness | 2016 |
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hyperglycemia; Hyperuricemia; Hypoglycemia; Hypoglycemic Agents; Membrane Transport Modulators; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Uric Acid | 2018 |
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
Topics: Benzhydryl Compounds; Blood Pressure; Canagliflozin; Disease Progression; Glomerular Filtration Rate; Glucose; Glucosides; Humans; Hypoglycemic Agents; Inflammation; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2018 |
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.
Topics: Aged; Colchicine; Gout; Heart Failure; Humans; Male; Stroke Volume; Uric Acid; Ventricular Function, Left | 2023 |
6 trial(s) available for uric acid and dapagliflozin
| Article | Year |
|---|---|
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Blood Pressure Determination; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Hemorheology; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Renin-Angiotensin System; Systole; Uric Acid | 2016 |
Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
Topics: Adolescent; Adult; Benzhydryl Compounds; Bumetanide; Drug Interactions; Female; Glucosides; Healthy Volunteers; Humans; Hyperuricemia; Male; Middle Aged; Natriuresis; Renal Elimination; Risk Assessment; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Uric Acid; Young Adult | 2018 |
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Topics: Adult; Benzhydryl Compounds; Cross-Over Studies; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Female; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Naphthalenes; Propionates; Pyridines; Treatment Outcome; United States; Uric Acid; Uricosuric Agents; Young Adult | 2021 |
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
Liraglutide Plus Dapagliflozin for High Uric Acid and Microalbuminuria in Diabetes Mellitus Complicated With Metabolic Syndrome.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucosides; Glycolipids; Humans; Liraglutide; Metabolic Syndrome; Quality of Life; Stroke Volume; Uric Acid; Ventricular Function, Left | 2022 |
Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus.
Topics: Diabetes Mellitus; Glomerular Filtration Rate; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2023 |
4 other study(ies) available for uric acid and dapagliflozin
| Article | Year |
|---|---|
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Kidney Failure, Chronic; Metformin; Microcirculation; Middle Aged; Myocardial Infarction; Nutrition Surveys; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Uric Acid | 2014 |
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renin-Angiotensin System; Risk Factors; Uric Acid | 2020 |
Sodium-glucose cotransporter 2 inhibitor treatment lowers serum uric acid in patients with heart failure with reduced ejection fraction - lessons from clinical trials. Letter regarding the article 'Dapagliflozin reduces uric acid concentration, an indepen
Topics: Diabetes Mellitus, Type 2; Glucose; Heart Failure; Humans; Sodium; Stroke Volume; Uric Acid; Ventricular Dysfunction, Left | 2022 |
The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD.
Topics: Aged; Benzhydryl Compounds; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Uric Acid | 2023 |